(Q37514167)

20 August 2017

1 reference

title

Pharmacotherapy of cerebral ischemia (English)

1 reference

20 August 2017

0 references

1 reference

6

E Sander Connolly

1 reference

20 August 2017

Andrew F Ducruet

1

1 reference

20 August 2017

Bartosz T Grobelny

2

1 reference

20 August 2017

Brad E Zacharia

3

1 reference

20 August 2017

Zachary L Hickman

4

1 reference

20 August 2017

Mason L Yeh

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

Expert Opinion on Pharmacotherapy

20 August 2017

published in

1 reference

20 August 2017

volume

10

1 reference

20 August 2017

issue

12

1 reference

20 August 2017

page(s)

1895-1906

1 reference

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Tissue plasminogen activator for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Current status of neuroprotection for cerebral ischemia: synoptic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

The role of thrombolysis in acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Thrombolytic therapy with streptokinase in acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Comparison of tissue plasminogen activator administration management between Telestroke Network hospitals and academic stroke centers: the Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Stroke units, tissue plasminogen activator, aspirin and neuroprotection: which stroke intervention could provide the greatest community benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Aggressive mechanical clot disruption and low-dose intra-arterial third-generation thrombolytic agent for ischemic stroke: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Is intra-arterial thrombolysis safe after full-dose intravenous recombinant tissue plasminogen activator for acute ischemic stroke?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Acute ischemic stroke: imaging-guided tenecteplase treatment in an extended time window.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Acute human stroke studied by whole brain echo planar diffusion-weighted magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multicenter study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of a randomized phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

The combined approach to lysis utilizing eptifibatide and rt-PA in acute ischemic stroke: the CLEAR stroke trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Argatroban tPA stroke study: study design and results in the first treated cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Dihydropyridine calcium antagonists increase fibrinolytic activity: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Mannitol use in acute stroke: case fatality at 30 days and 1 year

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Antiedema therapy in ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Clinical trials for cytoprotection in stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

NXY-059 for the treatment of acute stroke: pooled analysis of the SAINT I and II Trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

NXY-059 for acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

On the Analysis and Interpretation of Outcome Measures in Stroke Clinical Trials: Lessons From the SAINT I Study of NXY-059 for Acute Ischemic Stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

1,026 experimental treatments in acute stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Recommendations for standards regarding preclinical neuroprotective and restorative drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Methodological quality of animal studies of neuroprotective agents currently in phase II/III acute ischemic stroke trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Multifunctional actions of approved and candidate stroke drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Erythropoietin-induced neurovascular protection, angiogenesis, and cerebral blood flow restoration after focal ischemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Magnesium gates glutamate-activated channels in mouse central neurones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Reduction of infarct volume by magnesium after middle cerebral artery occlusion in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Neuroprotective effects of preischemia intraarterial magnesium sulfate in reversible focal cerebral ischemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

A randomized dose-response trial of citicoline in acute ischemic stroke patients. Citicoline Stroke Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

A randomized efficacy trial of citicoline in patients with acute ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Effects of citicoline on phospholipid and glutathione levels in transient cerebral ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Molecular mechanisms underlying neuroprotective effects of albumin after ischemic stroke.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Docosahexaenoic acid complexed to albumin elicits high-grade ischemic neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Albumin therapy of transient focal cerebral ischemia: in vivo analysis of dynamic microvascular responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Albumin therapy improves local vascular dynamics in a rat model of primary microvascular thrombosis: a two-photon laser-scanning microscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Albumin ameliorates tissue plasminogen activator-mediated blood-brain barrier permeability and ischemic brain injury in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656560903055095

10.1517/14656560903055095

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference